SCHEMBL5756005

SCHEMBL5756005

O=C(c1ccc(Cl)cc1)c1ccc2[nH]c(=O)cc(-c3cccs3)c2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
RXFP1 Q9HBX9 1/20 0.44
CHEK1 O14757 1/20 0.42
WEE1 P30291 1/20 0.42
CNR1 P21554 4/20 0.39
LMNA P02545 2/20 0.39
MAPT P10636 3/20 0.39
ADORA3 P0DMS8 1/20 0.39
ADORA2A P29274 1/20 0.39
RAB9A P51151 1/20 0.39
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
UBASH3B Q8TF42 1/20 0.38
F2 P00734 1/20 0.37
HTT P42858 1/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
GRIN1 Q05586 1/20 0.37
GRIN2A Q12879 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1538310 0.78 MEN1 (0.59) MEN1KMT2ARXFP1CHEK1WEE1
SCHEMBL5758311 0.78 LMNA (0.47) MEN1KMT2ARXFP1CNR1LMNA
SCHEMBL17025452 0.77 KDM4E (0.49) MEN1KMT2ARXFP1CNR1LMNA
SCHEMBL5757851 0.76 MAPT (0.39) MEN1KMT2ALMNAMAPT
SCHEMBL5722642 0.75 MEN1 (0.52) MEN1KMT2ARXFP1CNR1LMNA
SCHEMBL5780432 0.75 RXFP1 (0.52) MEN1KMT2ARXFP1CHEK1WEE1
SCHEMBL5550240 0.75 MEN1 (0.49) MEN1KMT2ARXFP1CHEK1WEE1
SCHEMBL5756770 0.75 KDM4E (0.53) MEN1KMT2ARXFP1CNR1LMNA
SCHEMBL5470078 0.74 PDE2A (0.48) MEN1KMT2ARXFP1CHEK1WEE1
SCHEMBL7701644 0.74 KMT2A (0.41) MEN1KMT2ARXFP1CNR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060135769-A1 Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives ANGIBAUD PATRICK R 2006-06-22 US disclosed
EP-1351954-B1 FARNESYL TRANSFERASE INHIBITING 4-HETEROCYCLYL-QUINOLINE AND QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2006-05-03 EP disclosed
US-20040067968-A1 Farnesyl transferase inhibiting 4-heterocyclyl quinoline and quinazoline JANSSEN PHARMACEUTICA, N.V. (BE) 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067968-A1 Farnesyl transferase inhibiting 4-heterocyclyl quinoline and quinazoline FNTA, FNTB, ACAT2 MEN1 1226/4885KMT2A 2507/4885RXFP1 2496/4885
US-20060135769-A1 Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives FNTA, FNTB, RABGGTB MEN1 858/4885KMT2A 2356/4885RXFP1 2106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.